Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780459 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6776171 | 0.93 | KDM4E (0.45) | SMN1; SMN2ALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL6776165 | 0.93 | KDM4E (0.45) | SMN1; SMN2ALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL6776397 | 0.92 | MAPT (0.49) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6776403 | 0.92 | MAPT (0.49) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6771330 | 0.91 | HSD17B10 (0.41) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6771328 | 0.91 | HSD17B10 (0.41) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6775582 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6775585 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2RXFP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL6775329 | 0.87 | HSD17B10 (0.38) | SMN1; SMN2RXFP1ALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225145-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2003-12-04 | — | — | US | claimed |
| US-6589969-B1 | A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-08 | — | — | US | claimed |
| EP-1122255-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-08-08 | — | — | EP | claimed |
| US-6821994-B2 | A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR REGULATOR, AN OXAZOL-4-YL-METHYLFURAN-2-YL-2-PROPENYLTHIO- OR SULFONYL- OR SULFINYL-ACETIC ACID OR METHYL ESTER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20030225145-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6589969-B1 | A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-08 | — | — | US | disclosed |
| EP-1122255-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225145-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | SMN1; SMN2 4662/4885RXFP1 1210/4885ALDH1A1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.